The Ensign Group (ENSG) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
12 May, 2026Executive summary
Achieved record same-store and transitioning occupancy rates of 84.3% and 85.1% in Q1 2026, with strong growth in skilled mix, Medicare revenue, and managed care census year-over-year.
Revenue for Q1 2026 increased 18.4% year-over-year to $1.39 billion, driven by higher occupancy, rate increases, and acquisitions.
Net income attributable to shareholders rose 24.2% to $99.7 million, with diluted EPS up 21.9% to $1.67 and adjusted EPS up 21.7% to $1.85.
Added 22 new operations in the quarter, including 21 real estate assets, expanding presence in Texas, Arizona, and Wisconsin; portfolio now includes 395 healthcare operations across 17 states.
Maintains a diversified business model with real estate ownership, new ventures, and a captive REIT structure for capital flexibility.
Financial highlights
GAAP diluted EPS rose 21.9% to $1.67; adjusted diluted EPS up 21.7% to $1.85 year-over-year.
Consolidated GAAP and adjusted revenues both increased 18.4% to $1.39 billion.
GAAP net income grew 24.2% to $99.7 million; adjusted net income up 23.9% to $110.2 million.
Adjusted EBITDA for Q1 2026 was $171.2 million; adjusted EBITDAR reached $236.7 million.
Cash and cash equivalents at $539.5 million; cash flow from operations $100.2 million.
Outlook and guidance
Raised 2026 annual earnings guidance to $7.48–$7.62 per diluted share and revenue to $5.81–$5.86 billion, with midpoint EPS up 15% over 2025 and 37% over 2024.
Guidance incorporates acquisitions closed and expected through Q2 2026, assumes 60 million diluted shares, 25% tax rate, and excludes stock-based compensation and system implementation costs.
Management expects continued growth from recent and pending acquisitions, with $342.4 million in real estate purchases pending.
Anticipates typical seasonality with lighter Q2/Q3 skilled mix and stronger Q4.
Latest events from The Ensign Group
- Director elections, auditor ratification, and say-on-pay up for vote at annual meeting.ENSG
Proxy filing2 Apr 2026 - 2025 saw record growth, enhanced governance, and performance-driven executive compensation.ENSG
Proxy filing2 Apr 2026 - Strong growth, robust acquisitions, and proactive regulatory management drive future upside.ENSG
Oppenheimer 36th Annual Healthcare MedTech & Services Conference19 Mar 2026 - Record revenue, earnings, and occupancy drive double-digit FY26 growth outlook.ENSG
Q4 20256 Feb 2026 - Q3 revenue up 15%, net income up 22.8%, and guidance raised amid record occupancy and expansion.ENSG
Q3 20245 Feb 2026 - Record Q2 growth, raised 2024 guidance, and continued disciplined expansion.ENSG
Q2 20242 Feb 2026 - Growth is fueled by leadership, local empowerment, and disciplined acquisitions amid a stable regulatory outlook.ENSG
Stephens 26th Annual Investment Conference | NASH202413 Jan 2026 - Record 2024 results and strong 2025 outlook driven by growth, acquisitions, and financial strength.ENSG
Q4 202426 Dec 2025 - Q1 2025 revenue up 16.1%, net income up 16.6%, and 2025 guidance raised after record growth.ENSG
Q1 202522 Dec 2025